About
LoQus23 Therapeutics develops small molecule inhibitors targeting somatic DNA repeat expansions to treat Huntington’s Disease and other triplet repeat expansion disorders by slowing DNA instability and neurodegeneration.
Explore LoQus23 Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.